Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30893642 | 0.90 | MITF (0.43) | MAPTPOLBMITFALDH1A1AR | |
| SCHEMBL28881823 | 0.83 | MAPT (0.54) | MAPTPOLBALDH1A1L3MBTL1KMT2A | |
| SCHEMBL25106583 | 0.82 | MITF (0.43) | MAPTPOLBMITFALDH1A1HTT | |
| SCHEMBL25106760 | 0.80 | MITF (0.41) | MAPTPOLBMITFALDH1A1AR | |
| SCHEMBL28720076 | 0.78 | IDO1 (0.45) | MAPTALDH1A1L3MBTL1KMT2ALMNA | |
| SCHEMBL1993428 | 0.78 | ENO1 (0.37) | MAPTPOLBMITFALDH1A1AR | |
| SCHEMBL11776821 | 0.78 | LMNA (0.40) | MAPTMITFALDH1A1LMNAKDM4E | |
| SCHEMBL998243 | 0.75 | IDO1 (0.43) | KMT2ALMNAKDM4ENPC1RAB9A | |
| SCHEMBL28616856 | 0.75 | IDO1 (0.47) | MAPTALDH1A1KMT2ALMNAKDM4E | |
| SCHEMBL1979899 | 0.75 | CSNK1D (0.49) | MAPTPOLBALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583303-B | Tripterine conjugates and uses thereof | 瑞阳公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025056913-A1 | COMPOUND AND METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-20 | — | — | WO | disclosed |
| CN-118955393-A | 2, 4-Dinitrophenoxy compound and preparation method thereof | 江南大学 | 2024-11-15 | — | — | CN | disclosed |
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2024-10-15 | — | — | US | disclosed |
| WO-2024159211-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-118206492-A | 2, 4-Dinitrophenoxy compound and preparation method thereof | 江南大学 | 2024-06-18 | — | — | CN | disclosed |
| CN-117756848-A | TH-302 derivative and preparation method thereof | 常州大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-115745975-B | JAK kinase domain and pseudokinase domain co-inhibition prodrug, preparation method and medical application | 中国药科大学 | 2023-11-24 | — | — | CN | disclosed |
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | REYOUNG CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
| EP-1896040-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1622608-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Threshold Pharmaceuticals, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004087075-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
| US-3987053-A | ANTIMICROBIAL | GRUPPO LEPETIT S.P.A. (IT) | 1976-10-19 | — | — | US | disclosed |
| US-3954789-A | 2-Nitroimidazole derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | BCR, FCGR2A, FCGRT | MAPT 99/4885POLB 2563/4885MITF 3422/4885 |
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | TLR9, XIAP, ENPP2 | MAPT 2281/4885POLB 3973/4885MITF 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.